[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMpHssrjgkT55i6RcJjgUqcX_-5KPn_urmplenAndBhw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Barretos Cancer Hospital",[4],48,false,4,5,17312,1,35,[14,16,19,21,24,26,28,30],{"name":15,"count":8},"Cervical Intraepithelial Neoplasia",{"name":17,"count":18},"Breast Cancer",3,{"name":20,"count":18},"Cancer",{"name":22,"count":23},"Acute Kidney Injury",2,{"name":25,"count":23},"Infection",{"name":27,"count":23},"Cervical Cancer",{"name":29,"count":23},"Anxiety Disorders",{"name":31,"count":23},"Biomarkers",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06356012","Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod","2026-12-31","Imiquimod",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,83,111,129,155,173,202,229,247,274,292,317,343,374,396,418,443,472],{"intervention":37,"totalTrials":23,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":67,"PHASE4":69,"NA":81},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":50},[55],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":66},"NCT03233412","Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions","COMPLETED",[41],"2020-01-14","2018-01-01",90,[64,65],"High Grade Intraepithelial Neoplasia","Cervix Cancer",[37],{"trials":68,"activeCount":50},[],{"trials":70,"activeCount":11,"soonestReadout":36},[71],{"nctId":34,"briefTitle":35,"status":72,"phases":73,"primaryCompletion":36,"completion":74,"start":75,"enrollment":76,"conditions":77,"interventions":80},"RECRUITING",[43],"2028-12-31","2024-04-02",96,[78,79,31],"HSIL, High-Grade Squamous Intraepithelial Lesions","Vaginal Microbiome",[37],{"trials":82,"activeCount":50},[],{"intervention":84,"totalTrials":11,"cells":85},"Induction chemotherapy",{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":107,"NA":109},{"trials":87,"activeCount":50},[],{"trials":89,"activeCount":50},[],{"trials":91,"activeCount":50},[],{"trials":93,"activeCount":50},[94],{"nctId":95,"briefTitle":96,"status":97,"phases":98,"primaryCompletion":99,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":105},"NCT03815903","Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma","UNKNOWN",[42],"2020-12","2025-12","2018-12-19",434,[104],"Locally Advanced Malignant Neoplasm",[84,106],"Chemoradiotherapy",{"trials":108,"activeCount":50},[],{"trials":110,"activeCount":50},[],{"intervention":106,"totalTrials":11,"cells":112},{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":125,"NA":127},{"trials":114,"activeCount":50},[],{"trials":116,"activeCount":50},[],{"trials":118,"activeCount":50},[],{"trials":120,"activeCount":50},[121],{"nctId":95,"briefTitle":96,"status":97,"phases":122,"primaryCompletion":99,"completion":100,"start":101,"enrollment":102,"conditions":123,"interventions":124},[42],[104],[84,106],{"trials":126,"activeCount":50},[],{"trials":128,"activeCount":50},[],{"intervention":130,"totalTrials":11,"cells":131},"5-ALA Photodynamic Therapy",{"EARLY_PHASE1":132,"PHASE1":134,"PHASE2":136,"PHASE3":138,"PHASE4":151,"NA":153},{"trials":133,"activeCount":50},[],{"trials":135,"activeCount":50},[],{"trials":137,"activeCount":50},[],{"trials":139,"activeCount":50},[140],{"nctId":141,"briefTitle":142,"status":58,"phases":143,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT01459393","Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment",[42],"2011-11","2010-11",137,[148],"Actinic Keratosis",[130,150],"Cryotherapy with liquid nitrogen",{"trials":152,"activeCount":50},[],{"trials":154,"activeCount":50},[],{"intervention":150,"totalTrials":11,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":169,"NA":171},{"trials":158,"activeCount":50},[],{"trials":160,"activeCount":50},[],{"trials":162,"activeCount":50},[],{"trials":164,"activeCount":50},[165],{"nctId":141,"briefTitle":142,"status":58,"phases":166,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":167,"interventions":168},[42],[148],[130,150],{"trials":170,"activeCount":50},[],{"trials":172,"activeCount":50},[],{"intervention":174,"totalTrials":11,"cells":175},"Carboplatin",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":196,"PHASE4":198,"NA":200},{"trials":177,"activeCount":50},[],{"trials":179,"activeCount":50},[],{"trials":181,"activeCount":50},[182],{"nctId":183,"briefTitle":184,"status":58,"phases":185,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":192},"NCT02978495","Neoadjuvant Carboplatin in Triple Negative Breast Cancer",[41],"2019-12-02","2021-10-22","2017-05-17",154,[191],"BRCA1 Hereditary Breast and Ovarian Cancer Syndrome",[193,174,194,195],"Doxorubicin","Paclitaxel","Cyclophosphamide",{"trials":197,"activeCount":50},[],{"trials":199,"activeCount":50},[],{"trials":201,"activeCount":50},[],{"intervention":203,"totalTrials":11,"cells":204},"metformin",{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":223,"PHASE4":225,"NA":227},{"trials":206,"activeCount":50},[],{"trials":208,"activeCount":50},[],{"trials":210,"activeCount":50},[211],{"nctId":212,"briefTitle":213,"status":97,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":221},"NCT01930864","Metformin Plus Irinotecan for Refractory Colorectal Cancer",[41],"2020-12-01","2015-09-01",41,[219,220],"Colorectal Neoplasms","Adenocarcinoma",[203,222],"irinotecan",{"trials":224,"activeCount":50},[],{"trials":226,"activeCount":50},[],{"trials":228,"activeCount":50},[],{"intervention":222,"totalTrials":11,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":241,"PHASE4":243,"NA":245},{"trials":232,"activeCount":50},[],{"trials":234,"activeCount":50},[],{"trials":236,"activeCount":50},[237],{"nctId":212,"briefTitle":213,"status":97,"phases":238,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":239,"interventions":240},[41],[219,220],[203,222],{"trials":242,"activeCount":50},[],{"trials":244,"activeCount":50},[],{"trials":246,"activeCount":50},[],{"intervention":248,"totalTrials":11,"cells":249},"sodium bicarbonate",{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":268,"PHASE4":270,"NA":272},{"trials":251,"activeCount":50},[],{"trials":253,"activeCount":50},[],{"trials":255,"activeCount":50},[256],{"nctId":257,"briefTitle":258,"status":58,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":266},"NCT00540904","Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate",[41],"2008-08","2009-09","2007-09",27,[265],"Radiographic Contrast Agent Nephropathy",[248,267],"NaCl",{"trials":269,"activeCount":50},[],{"trials":271,"activeCount":50},[],{"trials":273,"activeCount":50},[],{"intervention":267,"totalTrials":11,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":286,"PHASE4":288,"NA":290},{"trials":277,"activeCount":50},[],{"trials":279,"activeCount":50},[],{"trials":281,"activeCount":50},[282],{"nctId":257,"briefTitle":258,"status":58,"phases":283,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":284,"interventions":285},[41],[265],[248,267],{"trials":287,"activeCount":50},[],{"trials":289,"activeCount":50},[],{"trials":291,"activeCount":50},[],{"intervention":293,"totalTrials":11,"cells":294},"Induction TP chemotherapy",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":311,"PHASE4":313,"NA":315},{"trials":296,"activeCount":50},[],{"trials":298,"activeCount":50},[],{"trials":300,"activeCount":50},[301],{"nctId":302,"briefTitle":303,"status":58,"phases":304,"primaryCompletion":145,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT00959387","Induction Chemotherapy for Advanced Head and Neck Cancer",[41],"2013-04","2009-08",60,[309],"Head and Neck Cancer",[293],{"trials":312,"activeCount":50},[],{"trials":314,"activeCount":50},[],{"trials":316,"activeCount":50},[],{"intervention":318,"totalTrials":11,"cells":319},"Valproic Acid",{"EARLY_PHASE1":320,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":321,"activeCount":50},[322],{"nctId":323,"briefTitle":324,"status":58,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":332},"NCT02608736","Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid",[39],"2016-12","2017-07","2015-12",42,[331],"Head and Neck Squamous Cell Carcinoma",[318],{"trials":334,"activeCount":50},[],{"trials":336,"activeCount":50},[],{"trials":338,"activeCount":50},[],{"trials":340,"activeCount":50},[],{"trials":342,"activeCount":50},[],{"intervention":193,"totalTrials":23,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":346,"activeCount":50},[],{"trials":348,"activeCount":50},[],{"trials":350,"activeCount":50},[351],{"nctId":183,"briefTitle":184,"status":58,"phases":352,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":353,"interventions":354},[41],[191],[193,174,194,195],{"trials":356,"activeCount":50},[],{"trials":358,"activeCount":50},[],{"trials":360,"activeCount":50},[361],{"nctId":362,"briefTitle":363,"status":97,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT00820690","Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer",[],"2012-04","2017-09","2008-07",80,[17],[371,372,373],"doxorubicin","cyclophosphamide","paclitaxel",{"intervention":194,"totalTrials":23,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":386,"PHASE4":388,"NA":390},{"trials":377,"activeCount":50},[],{"trials":379,"activeCount":50},[],{"trials":381,"activeCount":50},[382],{"nctId":183,"briefTitle":184,"status":58,"phases":383,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":384,"interventions":385},[41],[191],[193,174,194,195],{"trials":387,"activeCount":50},[],{"trials":389,"activeCount":50},[],{"trials":391,"activeCount":50},[392],{"nctId":362,"briefTitle":363,"status":97,"phases":393,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":394,"interventions":395},[],[17],[371,372,373],{"intervention":195,"totalTrials":23,"cells":397},{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":399,"activeCount":50},[],{"trials":401,"activeCount":50},[],{"trials":403,"activeCount":50},[404],{"nctId":183,"briefTitle":184,"status":58,"phases":405,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":406,"interventions":407},[41],[191],[193,174,194,195],{"trials":409,"activeCount":50},[],{"trials":411,"activeCount":50},[],{"trials":413,"activeCount":50},[414],{"nctId":362,"briefTitle":363,"status":97,"phases":415,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":416,"interventions":417},[],[17],[371,372,373],{"intervention":419,"totalTrials":11,"cells":420},"Weekly cisplatin",{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":422,"activeCount":50},[],{"trials":424,"activeCount":50},[],{"trials":426,"activeCount":50},[],{"trials":428,"activeCount":50},[],{"trials":430,"activeCount":50},[],{"trials":432,"activeCount":50},[433],{"nctId":434,"briefTitle":435,"status":97,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},"NCT03194061","Hypofractionated Radiotherapy and Concurrent Cisplatin for Head and Neck Cancer",[44],"2019-08-31","2015-01-01",20,[441],"Radiotherapy; Complications",[419],{"intervention":444,"totalTrials":11,"cells":445},"antibiotic prophylaxis",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":456},{"trials":447,"activeCount":50},[],{"trials":449,"activeCount":50},[],{"trials":451,"activeCount":50},[],{"trials":453,"activeCount":50},[],{"trials":455,"activeCount":50},[],{"trials":457,"activeCount":50},[458],{"nctId":459,"briefTitle":460,"status":58,"phases":461,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":471},"NCT06801405","Antibiotic Prophylaxis in Percutaneous Nephrostomy Placements and Replacements for Malignant Urinary Tract Obstruction",[],"2024-10-10","2021-04-02",320,[466,467,22,468,469,470],"Ureteral Obstruction","Neoplasms","Nephrostomy; Complications","Antibiotic Prophylaxis","Urinary Tract Infections",[444],{"intervention":473,"totalTrials":11,"cells":474},"Indocyanine green",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":476,"activeCount":50},[],{"trials":478,"activeCount":50},[],{"trials":480,"activeCount":50},[],{"trials":482,"activeCount":50},[],{"trials":484,"activeCount":50},[],{"trials":486,"activeCount":50},[487],{"nctId":488,"briefTitle":489,"status":97,"phases":490,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":498},"NCT02142244","Fluorescence Surgery for Sentinel Node Identification in Melanoma",[44],"2018-12","2021-12","2014-05",318,[496,497],"Melanoma","Lymph Node Metastasis",[473]]